Nitisinone


Nitisinone
Nitisinone
Systematic (IUPAC) name
2-[2-nitro-4-(trifluoromethyl)benzoyl]
cyclohexane-1,3-dione
Clinical data
AHFS/Drugs.com Consumer Drug Information
Licence data EMA:LinkUS FDA:link
Pregnancy cat.  ?
Legal status -only (US)
Routes Oral
Pharmacokinetic data
Half-life Approximately 54 h
Identifiers
CAS number 104206-65-7 YesY
ATC code A16AX04
PubChem CID 115355
DrugBank APRD01141
ChemSpider 103195 YesY
UNII K5BN214699 YesY
KEGG D05177 N
ChEBI CHEBI:50378 N
ChEMBL CHEMBL1337 N
Chemical data
Formula C14H10F3NO5 
Mol. mass 329.228 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Nitisinone (also known as NTBC, an abbreviation of its full chemical name) is a drug originally developed as an herbicide now used in the treatment of hereditary tyrosinemia type 1. Since its first use for this indication in 1991, it has replaced liver transplantation as the first-line treatment for this rare condition.[1] It is also being studied in the less severe but related condition alkaptonuria.[2] It is marketed under the brand name Orfadin.

The mechanism of action of nitrisinone involves reversibile inhibition of 4-hydroxyphenylpyruvate oxidase,[3] [4] thus preventing the formation of maleylacetoacetic acid and fumarylacetoacetic acid, which have the potential to be converted to succinyl acetone, a toxin that damages the liver and kidneys.[1]

Chem

Nitisinone.png

Anon US application 19,920,903,691 .

References

  1. ^ a b McKiernan PJ (2006). "Nitisinone in the treatment of hereditary tyrosinaemia type 1". Drugs 66 (6): 743–50. doi:10.2165/00003495-200666060-00002. PMID 16706549. 
  2. ^ Phornphutkul C, Introne WJ, Perry MB et al. (2002). "Natural history of alkaptonuria". New England Journal Medicine 347 (26): 2111–21. doi:10.1056/NEJMoa021736. PMID 12501223. http://content.nejm.org/cgi/content/full/347/26/2111. 
  3. ^ Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, Smith LL, Prisbylla MP, Mutter LC, Lee DL (1998). "From toxicological problem to therapeutic use: The discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug". Journal of Inherited Metabolic Disease 42 (21): 498–506. doi:10.1023/A:1005458703363. PMID 9728330. 
  4. ^ Kavana M, Moran GR (2003). "Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione". Biochemistry 42 (34): 10238–45. doi:10.1021/bi034658b. PMID 12939152.